Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20363465 | 0.84 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2818339 | 0.81 | CDK2 (0.41) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL12394764 | 0.80 | CCNE1 (0.38) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL18174959 | 0.79 | CDK2 (0.40) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL2629266 | 0.78 | SLC6A3 (0.44) | FDPSALDH1A1SMN1; SMN2NOS1POLB | |
| SCHEMBL13533948 | 0.78 | CDK2 (0.39) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL12417805 | 0.77 | CCNE1 (0.36) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL12394759 | 0.77 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2POLBTLR8TLR7 | |
| SCHEMBL23558952 | 0.76 | CCNE1 (0.38) | CDK2CCNE1CDK5FDPSALDH1A1 | |
| SCHEMBL14425148 | 0.76 | CCNE1 (0.38) | CDK2CCNE1CDK5FDPSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CDK2 40/4885CCNE1 91/4885CDK5 142/4885 |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | CDK2 53/4885CCNE1 104/4885CDK5 115/4885 |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | CDK2 15/4885CCNE1 112/4885CDK5 31/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CDK2 150/4885CCNE1 189/4885CDK5 325/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | CDK2 69/4885CCNE1 157/4885CDK5 148/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CDK2 40/4885CCNE1 91/4885CDK5 142/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CDK2 150/4885CCNE1 189/4885CDK5 325/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CDK2 130/4885CCNE1 339/4885CDK5 471/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CDK2 69/4885CCNE1 153/4885CDK5 227/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CDK2 150/4885CCNE1 189/4885CDK5 325/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | CDK2 15/4885CCNE1 112/4885CDK5 31/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CDK2 69/4885CCNE1 153/4885CDK5 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.